CCRN Cross Country Health

 

EXHIBIT 99.2

 

LIMITED POWER OF ATTORNEY

 

Know all by these present, that I, David J. Snyderman, hereby make, constitute and appoint each of Michael Turro, Karl Wachter and Hayley Stein, or any of them acting individually, and with full power of substitution, as my true and lawful attorney-in-fact for the purpose of executing in my name, (a) in my personal capacity or (b) in my capacity as Manager or in other capacities of Supernova Management LLC, a Delaware limited liability company, and each of its affiliates or entities advised or controlled by me or Supernova Management LLC, all documents, certificates, instruments, statements, filings and agreements (“documents”) to be filed with or delivered to the United States Securities and Exchange Commission (the “SEC”) pursuant to the Securities and Exchange Act of 1934, as amended (the “Act”), and the rules and regulations promulgated thereunder, including, without limitation, all documents relating to the beneficial ownership of securities required to be filed with the SEC pursuant to Section 13(d) or Section 16(a) of the Act, including, without limitation: (a) any acquisition statements on Schedule 13D or Schedule 13G and any amendments thereto, (b) any joint filing agreements pursuant to Rule 13d-1(k) under the Act, and (c) any initial statements of, or statements of changes in, beneficial ownership of securities on Form 3, Form 4 or Form 5.

 

All past acts of the attorney-in-fact in furtherance of the foregoing are hereby ratified and confirmed.

 

This Power of Attorney shall remain in full force and effect until the earlier of it being (a) revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (b) superseded by a new power of attorney regarding the purposes outlined herein as of a later date.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 22 day of December, 2022.

 

	/s/ David J. Snyderman
	David J. Snyderman

 

 

 

Exhibit 99.3

 

SCHEDULE A

 

Funds

 

Date		Number of Shares Bought				Price Per Share($) (1)(2)
12/19/2024			50,720				17.92479	(3)
12/20/2024			135,700				17.90460
12/23/2024			34,522				17.88283	(4)
12/24/2024			15,526				17.94974	(5)
12/26/2024			18,581				17.96386	(6)
12/27/2024			27,614				17.98054	(7)
12/30/2024			38,635				18.00899	(8)
12/31/2024			12,681				18.11968	(9)
1/2/2025			43,316				18.11946	(10)

 

TB(1) Excludes commissions and other execution-related costs.

(2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

(3) Reflects a weighted average purchase price of $17.92479 per share, at prices ranging from $17.9 to $17.95 per share.

(4) Reflects a weighted average purchase price of $17.88283 per share, at prices ranging from $17.84 to $17.91 per share.

(5) Reflects a weighted average purchase price of $17.94974 6per share, at prices ranging from $17.9 to $17.97 per share.

(6) Reflects a weighted average purchase price of $17.96386 per share, at prices ranging from $17.9 to $18.00 per share.

(7) Reflects a weighted average purchase price of $17.98054 per share, at prices ranging from $17.95 to $18.00 per share.

(8) Reflects a weighted average purchase price of $18.00899 per share, at prices ranging from $17.96 to $18.08 per share.

(9) Reflects a weighted average purchase price of $18.11968 per share, at prices ranging from $18.08 to $18.15 per share.

(10) Reflects a weighted average purchase price of $18.11946 per share, at prices ranging from $18.01 to $18.15 per share.

 

 

---